Anaptys discontinues ulcerative colitis trial after rosnilimab fails endpoints

Go back to Anaptys discontinues ulcerative colitis trial after rosnilimab fails endpoints
(NASDAQ: ANAB) Delayed: 47.94 --0 (-0%)
Previous Close $47.94    52 Week High $ 
Open $47.94    52 Week Low $ 
Day High $47.94    P/E N/A 
Day Low $47.94    EPS $ 
Volume 2,300